Highlights LianBio

Equities

LIANY

US53000N1081

Market Closed - OTC Markets Other stock markets 12:57:15 18/05/2024 am IST			5-day change	1st Jan Change
0.3256 ^USD	+7.73%		+1.75%	-92.72%

10/05	China's Zeekr prices US IPO at top of range to raise $441 million	RE
07/05	Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China's Zeekr prices US IPO at top of range to raise $441 million	10/05	RE
Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	07/05	MT
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	13/02	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	27/12	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	27/12	MT
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	26/12	CI
LianBio Rejects Concentra Biosciences' Unsolicited Acquisition Proposal	07/12	MT
Concentra Biosciences, LLC cancelled the acquisition of LianBio from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.	06/12	CI
LianBio Receives Unsolicited Proposal From Concentra Biosciences to be Acquired for $4.30 Per Share Plus Contingent Value Right	02/12	MT
Concentra Biosciences, LLC submit non-binding proposal to acquire LianBio.	30/11	CI
LianBio Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	31/23/31	CI
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023	26/23/26	CI
LianBio Signs Agreement With Bristol-Myers Squibb on Exclusive Rights to Mavacamten in China, Other Asian Markets	24/23/24	MT
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets	24/23/24	CI
LianBio Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	04/23/04	CI
LianBio, Tarsus Pharmaceuticals Get US FDA Approval For Xdemvy in Treating Eye Disease Demodex Blepharitis	26/23/26	MT
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	12/23/12	CI
LianBio Says Its Camzyos Drug Receives Marketing Approval From Singapore Health Sciences Authority	26/23/26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LianBio

Equities

LIANY

US53000N1081

Highlights

Filters